CoChat

Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer

Open access
Liu, Xiaomin, Wang, Ping, Zhang, Caiyan, Ma, Zhongliang · 2017 · Oncotarget
Cited by 216

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

// Xiaomin Liu 1, * , Ping Wang 1, * , Caiyan Zhang 1 and Zhongliang Ma 1 1 Lab for Noncoding RNA and Cancer, School of Life Sciences, Shanghai University, 200444 Shanghai, China * These authors contributed equally to this work Correspondence to: Zhongliang Ma, email: zlma@shu.edu.cn Keywords: epidermal growth factor receptor (EGFR), noncoding RNA, precision medicine, lung cancer Received: October 11, 2016 Accepted: March 24, 2017 Published: April 05, 2017 ABSTRACT Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role of noncoding RNA regulatory networks has been more and more reveal. EGFR has been identified as an oncogenic driver of NSCLC, especially activating mutations EGFR and its inhibition with specific TKIs can generate dramatic tumor responses. Studies have shown that EGFR plays significant roles in the progression of NSCLC. Subset analysis of the small proportion of patients with EGFR-mutant lung cancer showed a disease-free survival benefit, but was underpowered to detect a survival advantage. Herein, we highlight the progression of EGFR, noncoding RNA, and their roles in carcinogenesis. We also focus on anti-lung cancer drug development and EGFR-related drug resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.16854

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 216

Metadata

Authors
Liu, X., Wang, P., Zhang, C., & Ma, Z.
Venue
Oncotarget
Published
2017-04-05
Volume
8
Issue
30
Pages
50209-50220
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2604429430
Cited by
216
References
15
FWCI
10.73
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.